--- title: "ARA290 guide: EPO-derived repair peptide - PeptideSupermarket®" description: "ARA290, or cibinetide, is studied for innate repair receptor signalling, small fibre neuropathy and inflammation without raising red blood cells." url: "https://peptidesupermarket.co.uk/research/ara290-how-this-epo-derived-peptide-sends-a-repair-signal-without-raising-red-blood-cells" site: "PeptideSupermarket®" country: "United Kingdom" --- [Home](https://peptidesupermarket.co.uk) › [Research](https://peptidesupermarket.co.uk/research) › ARA290: how this EPO-derived peptide sends a repair signal without raising red blood cells [Back to Guides](https://peptidesupermarket.co.uk/research/category/guides) [Guides](https://peptidesupermarket.co.uk/research/category/guides) [ARA-290](https://peptidesupermarket.co.uk/research/peptide/ara-290) # ARA290: how this EPO-derived peptide sends a repair signal without raising red blood cells ARA290, also known as cibinetide, is studied for tissue protection, inflammation signalling and small fibre neuropathy models. Its appeal is its separation from EPO's red blood cell effects. Published 23 Aug 2026 9 min read Reference-backed All content is for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. [Read our full disclosure](https://peptidesupermarket.co.uk/disclosure). ## What is ARA-290? ARA-290 is a synthetic peptide derived from erythropoietin, usually shortened to EPO. It is also known as **cibinetide**. EPO is best known for its role in red blood cell production, but the parent molecule also has tissue-protective effects in stressed or injured cells. ARA-290 was designed to keep the repair-related signalling while avoiding the haematopoietic, red blood cell producing, activity that makes EPO unsuitable as a simple tissue-repair tool. The most useful way to think about ARA-290 is as a selective message rather than a broad stimulant. Many peptide discussions frame compounds as either increasing a pathway or blocking it. ARA-290 sits in a different category. It is studied because it appears to engage a protective receptor system associated with cellular stress responses, inflammatory control and nerve fibre integrity. In the research literature, ARA-290 is commonly described as an 11-amino-acid peptide based on the helix B surface region of EPO. That small structural slice matters. It is not simply mini-EPO. It was engineered to avoid the classical EPO receptor activity responsible for erythropoiesis, which is why researchers treat it as a distinct investigational compound. Want to compare ARA-290 prices in the UK? See our ARA-290 price comparison page here: [Compare ARA-290 peptide prices UK](https://peptidesupermarket.co.uk/peptide/ara-290). ## How is ARA-290 different from EPO? EPO is a natural hormone, mainly produced by the kidneys, that tells the bone marrow to make more red blood cells when oxygen delivery needs to increase. That function is vital in normal physiology. In drug form, however, stimulating red blood cell production can carry serious risks if used in the wrong setting, including thicker blood and a higher risk of clot-related complications. ARA-290 was developed to separate EPO's tissue-protective biology from its blood-forming biology. The distinction is central to almost every serious discussion of this peptide. ARA-290 is not studied as a blood-building agent. It is studied as an innate repair receptor ligand, with interest centred on inflammation, nerve stress and tissue protection. EPO is primarily associated with stimulating red blood cell production and increasing the blood's oxygen-carrying capacity. Its activity is mainly linked to classical erythropoietin receptor (EPOR) signalling in the bone marrow, and it can increase red blood cell mass and haematocrit. Research and clinical use of EPO include the treatment of certain types of anaemia, as well as research into oxygen biology and tissue protection. Licensed EPO medicines are available for specific medical indications. In comparison, ARA-290, also known as cibinetide, is being investigated for its tissue-protective and anti-inflammatory signalling in research models. Its activity is often associated with the innate repair receptor pathway, commonly described as involving an EPOR/CD131 receptor complex. Unlike EPO, it was designed to avoid significant stimulation of erythropoiesis and therefore is not intended to increase red blood cell mass or haematocrit. Current research interest includes neuropathic pain models, small-fibre neuropathy, inflammation, and tissue stress. ARA-290 (cibinetide) remains investigational and does not have routine approved clinical use. This is why ARA-290 attracts attention in nerve and inflammation research. The point is not to push the body to make more blood. The hypothesis is that it sends a repair-biased signal to tissues under stress. ## How does ARA-290 work through the innate repair receptor? ARA-290 is usually discussed in relation to the **innate repair receptor**, a receptor complex linked with the EPO receptor and the common beta receptor, also called CD131. This receptor system is described in tissue-protection research as distinct from the classical EPO receptor pathway in bone marrow. The proposed mechanism is that injured or inflamed tissues express receptor machinery that responds to protective ligands. When activated, this system can shift cellular behaviour away from damage signalling and towards survival, repair and resolution of inflammation. In nerve-focused models, that may mean a more supportive environment for small nerve fibres and less amplification of pain-related signalling. > ARA-290 should not be described as a painkiller in the usual sense. It is not understood as a numbing agent. The research question is whether it changes the stressed tissue environment that contributes to abnormal nerve signalling. Mechanistic papers have linked this pathway with reduced inflammatory signalling, improved cell survival under stress and protection against tissue injury in experimental systems. The biology is promising, but it is not fully settled. Receptor behaviour can vary by tissue type, disease model and experimental conditions, which is one reason findings in early studies need cautious interpretation. ## Why does ARA-290 not raise red blood cells? ARA-290 does not appear to activate the classical homodimeric EPO receptor pathway that drives red blood cell production in bone marrow. That is the key design feature. EPO itself can interact with receptor systems involved in both erythropoiesis and tissue protection. ARA-290 is based on a region intended to preserve protective signalling without triggering the red blood cell programme. This matters because red blood cell stimulation is not a minor side issue. In medical use, erythropoiesis-stimulating agents require careful supervision because excessive increases in haemoglobin or haematocrit can raise cardiovascular and thrombotic risk. A peptide being studied for nerve or inflammation biology would be far less useful if it also pushed red blood cell production. Early human studies of cibinetide have generally monitored haematological measures because of its EPO ancestry. The attraction of the compound is precisely that it has been reported as non-erythropoietic in the contexts studied. That does not make it risk-free. It means its risk profile is not expected to mirror conventional EPO in the specific respect of red blood cell production. ## What is ARA-290 studied for? ARA-290 research clusters around tissue stress rather than performance enhancement. The most discussed areas are inflammatory disease, neuropathic pain and small fibre neuropathy, particularly where nerve damage is linked with immune or metabolic stress. ### Inflammation and tissue stress Inflammation is useful when it is brief and targeted. Persistent inflammation is different. It can expose cells to damaging signals for long periods, making recovery harder and increasing the chance that nerves remain irritable. ARA-290 is studied because innate repair receptor activation may help dampen harmful inflammatory signalling while supporting protective cell responses. ### Neuropathic pain models Neuropathic pain comes from abnormal signalling in damaged or sensitised nerves. It can feel like burning, electric shocks, tingling or pain from light touch. The scientific appeal of ARA-290 is that it may influence the tissue conditions behind those signals, rather than simply trying to block perception of pain. ### Metabolic and immune-linked nerve injury Small nerve fibres can be damaged in diabetes, sarcoidosis and other conditions involving chronic inflammatory or metabolic stress. Cibinetide has therefore been studied in settings where small fibre structure and neuropathic symptoms can be measured over time, including corneal nerve fibre imaging in some trials. ## What is small fibre neuropathy, and why is ARA-290 linked to it? Small fibre neuropathy affects the thin nerve fibres that help detect pain, temperature and autonomic signals. These fibres are different from the larger nerves used for strength, reflexes and major movement. A person can have significant small fibre symptoms while standard nerve conduction tests look relatively normal, because those tests mainly assess larger fibres. Common descriptions include burning feet, pins and needles, stabbing sensations, altered temperature feeling and pain from light touch. Some people also report autonomic symptoms such as changes in sweating or heart-rate regulation, depending on which fibres are involved. ARA-290 is linked to small fibre neuropathy because early clinical work in sarcoidosis and type 2 diabetes explored whether cibinetide could improve neuropathic symptoms and objective nerve-fibre measures. One method used in this field is corneal confocal microscopy, which examines small nerve fibres in the cornea. It is attractive for research because it gives a repeatable, non-invasive window into small fibre structure. The strongest position to take is this: ARA-290 is one of the more biologically coherent peptides in small fibre neuropathy research, but it remains investigational. The mechanism fits the problem, and early signals are interesting, yet the evidence base is still too small for clinical certainty. ## What do human studies of cibinetide show so far? Human evidence for ARA-290, under the name cibinetide, is still early. Published work has included small studies in sarcoidosis-associated small fibre neuropathy and type 2 diabetes. These studies have looked at symptom scores, quality-of-life measures and nerve-fibre markers. Some reported favourable changes, including improvements in neuropathic symptoms or corneal nerve fibre measures. Those findings are not the same as a settled treatment effect. Small studies are vulnerable to placebo effects, selection bias and short follow-up. Neuropathic symptoms can also fluctuate, which makes controlled trial design especially important. The useful takeaway is that cibinetide has moved beyond purely theoretical biology, but it has not crossed into established medical practice. ARA-290 (cibinetide) has been investigated across several research areas, including sarcoidosis-associated small-fibre neuropathy, type 2 diabetes with neuropathic symptoms, inflammation and tissue-injury models, and haematological monitoring. Studies in sarcoidosis-associated small-fibre neuropathy have examined neuropathic symptoms, quality-of-life measures and small-fibre function, with early clinical findings suggesting potential benefits, although larger, well-controlled studies are needed to confirm efficacy. Research involving type 2 diabetes has examined metabolic measures, neuropathic symptoms and nerve-fibre assessments, providing a basis for further investigation rather than supporting routine clinical use. In inflammation and tissue-injury models, researchers have examined cell survival, inflammatory mediators and tissue-protection pathways, with preclinical findings supporting a biologically plausible tissue-protective and anti-inflammatory mechanism, while recognising that results can vary between experimental models and may not directly translate to humans. In relation to haematological parameters, ARA-290 is designed to provide tissue-protective signalling without stimulating erythropoiesis, and early studies have not characterised it as a red-blood-cell stimulant. For research comparison purposes, that puts ARA-290 in a middle category. It has a clear mechanistic rationale and human exploratory data, but it lacks the large, definitive trials that would be needed to support approved therapeutic claims. ## What are the main limitations and safety questions? The first limitation is scale. Much of the human literature is small, early phase or exploratory. That is normal for an investigational peptide, but it limits confidence. A signal in a focused trial population does not automatically generalise to other causes of nerve pain or inflammation. The second limitation is endpoint choice. Neuropathic pain is difficult to measure cleanly. Symptom scores matter, but they can be influenced by expectation and background care. Objective measures such as corneal nerve fibre density add weight, yet they still need to be tied to meaningful clinical outcomes in larger studies. Safety also needs a careful reading. ARA-290's non-erythropoietic design removes one major concern associated with EPO-like biology, but it does not answer every safety question. Long-term immune effects, interactions with disease biology and repeated exposure all require proper study. Research-grade material also raises separate concerns around identity, purity, storage and analytical verification. - **Do not assume EPO safety data applies directly.** ARA-290 is related to EPO, but it is designed to behave differently. - **Do not assume non-erythropoietic means harmless.** A compound can avoid red blood cell stimulation and still have other biological effects. - **Do not treat supplier claims as evidence.** Mechanism diagrams and product pages are not substitutes for peer-reviewed data. ## How should researchers interpret ARA-290 supplier and product claims? ARA-290 is often marketed in simple language: repair, nerve support, inflammation control. Those phrases can be useful shorthand, but they are not evidence on their own. A serious comparison should separate three things: the published biology of cibinetide, the analytical quality of a specific research product and any claim being made by a seller. For laboratory procurement, the basics matter. Researchers should look for clear identity testing, purity data, batch documentation and storage conditions. For any featured supplier, a claim should be judged against the certificate of analysis and the published literature, not against marketing language. [ARA-290](https://peptidesupermarket.co.uk/peptide/ara-290) is shown on this site, it should be read as a research product comparison rather than a recommendation for human use. ARA-290 remains an investigational peptide. The sensible standard is evidence first, product claims second. ## Frequently asked questions ### Is ARA-290 approved? ARA-290, also called cibinetide, is not approved as a routine medicine by major regulators such as the MHRA, FDA or EMA. It remains an investigational compound studied in research and clinical trial settings. ### Does ARA-290 increase red blood cells? ARA-290 was designed to avoid the classical EPO receptor signalling that increases red blood cell production. This non-erythropoietic profile is one of the main reasons it is studied separately from EPO. ### ARA-290 vs EPO, what is the difference? EPO is a hormone that can stimulate red blood cell production. ARA-290 is a small EPO-derived peptide designed to target tissue-protective repair signalling without acting as a blood-building agent. ### What is cibinetide? Cibinetide is another name for ARA-290. It refers to the same investigational EPO-derived peptide studied for innate repair receptor activation, inflammation biology and small fibre neuropathy research. ### What are ARA-290 side effects? Published early studies have generally focused on tolerability and the absence of EPO-like red blood cell stimulation, but the full safety profile is not settled. Long-term and wider population data remain limited. ### Is ARA-290 studied for small fibre neuropathy? Yes. Cibinetide has been studied in small fibre neuropathy contexts, including sarcoidosis-associated nerve symptoms and type 2 diabetes-related neuropathic symptoms. The evidence is preliminary. ### Is ARA-290 a painkiller? ARA-290 is not usually described as a conventional painkiller. It is studied for its potential effects on inflammation, nerve stress and tissue repair pathways that may contribute to neuropathic pain signalling. **Research disclaimer:** This article is for research and educational purposes only. It is not medical advice, it does not recommend human use, and it should not be used to guide treatment decisions. ## References - Brines M, Grasso G, Fiordaliso F, et al. [Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor](https://www.pnas.org/doi/10.1073/pnas.0406491101). *Proceedings of the National Academy of Sciences*, 2004. - Brines M, Cerami A. [The receptor that tames the innate immune response](https://pubmed.ncbi.nlm.nih.gov/22614618/). *Molecular Medicine*, 2012. - Brines M, Patel NSA, Villa P, et al. A nonerythropoietic peptide that mimics erythropoietin's tissue-protective activity. *Proceedings of the National Academy of Sciences*, 2008. - ClinicalTrials.gov. [Study records for cibinetide, ARA 290](https://clinicaltrials.gov/search?term=cibinetide%20ARA%20290), including neuropathy and inflammatory disease research. - PubChem. [Cibinetide compound records and identifiers](https://pubchem.ncbi.nlm.nih.gov/#query=cibinetide). National Center for Biotechnology Information. Price Comparison ### Compare ARA-290 prices across the UK Side-by-side prices from every trusted UK supplier stocking ARA-290. [Compare prices](https://peptidesupermarket.co.uk/peptide/ara-290) [All articles](https://peptidesupermarket.co.uk/research) Share copied = false, 2000)" aria-label="Copy link" class="w-8 h-8 rounded-full bg-bg-light hover:bg-primary hover:text-white text-text-muted flex items-center justify-center transition-colors cursor-pointer relative"> ### Featured Peptide #### ARA-290 Synthetic peptide investigated for its potential tissue-protective and anti-inflammatory effects [Compare prices](https://peptidesupermarket.co.uk/peptide/ara-290) ### More Guides [Browse all guides](https://peptidesupermarket.co.uk/research/category/guides) Keep Reading ## Related articles Guides ### AICAR Peptide Guide: Mechanism, Cost and Safety AICAR is discussed for endurance and metabolic research, but its high cost, anti-doping status and unresolved safety questions make it a highly specialised compound. 7 min read [AICAR Peptide Guide: Mechanism, Cost and Safety](https://peptidesupermarket.co.uk/research/aicar-peptide-guide-mechanism-cost-and-safety) Guides ### AHK-Cu Peptide Guide: Skin, Hair and Research Use AHK-Cu is a copper-binding tripeptide discussed for skin quality, tissue repair signalling and scalp support. This guide explains how it compares with GHK-Cu and why safety matters. 8 min read [AHK-Cu Peptide Guide: Skin, Hair and Research Use](https://peptidesupermarket.co.uk/research/ahk-cu-peptide-guide-skin-hair-and-research-use) Guides ### HMG fertility guide: FSH, LH and how menotropins are discussed in research HMG, or human menopausal gonadotropin, is discussed in fertility research because it provides both FSH and LH activity. This guide explains the mechanism, comparisons and key cautions. 6 min read [HMG fertility guide: FSH, LH and how menotropins are discussed in research](https://peptidesupermarket.co.uk/research/hmg-fertility-guide-fsh-lh-and-how-menotropins-are-discussed-in-research) --- *Add `.md` to any page URL on peptidesupermarket.co.uk for its Markdown version. Index of the site: https://peptidesupermarket.co.uk/llms.txt - full text: https://peptidesupermarket.co.uk/llms-full.txt.*